期刊文献+

糖尿病治疗的新武器——肠促胰素 被引量:2

Treatment of Diabetes Mellitus with Incretin
下载PDF
导出
摘要 肠促胰素是由肠道内分泌细胞合成分泌的激素,具有葡萄糖依赖性促胰岛素分泌的特性,可通过促进β细胞的胰岛素分泌、延缓胃排空、抑制食欲等多个途径参与血糖调节,甚至延缓或逆转2型糖尿病的进展。本文就肠促胰素将作为2型糖尿病治疗的新武器研究进展作一综述。 Incretins are hormones secreted from intestinal endocrine cells stimulated by meal nutrients. Incretins can maintain glucose through promoting insulin secretion from β cell as well as many other physiological effects. Furthermore can delay or even reverse the deterioration of type 2 diabetes. Research progress in incretins on diabetes mellitus is reviewed in this paper.
出处 《国际老年医学杂志》 2013年第2期70-72,共3页 International Journal of Geriatrics
关键词 肠促胰素 胰高血糖素样肽1 糖尿病 2型 Incretins Glucagon - like peptide - 1 Diabetes mellitus type 2
  • 相关文献

参考文献20

  • 1Hero SS. Diabetes and obesity: the twin epidemics [J]. Nat Med, 2005, 12:75-80.
  • 2Kim W, Egan JM. The role of incretins in ghucose homeostasis and diabetes treatment [J]. Pharmacol Rev, 2008, 60: 470-512.
  • 3Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide - 1 receptor agonists and dipeptidyl peptidase- 4 inhibitors in type 2 diabetes [ J ]. Lancet, 2006, 368, 1696 - 1705.
  • 4Kim SJ, Winter K, Nian C. GrIP stimulation of pancreatic beta -cell survival is dependent upon phosohatidylinositol 3 -kinase (PI3 -K ) /protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxol and downregulation of bax expression [ J]. J Biol Chem, 2005, 280:22297 -22307.
  • 5Salehi M, Aulinger BA, D' Alessio DA. Targeting β - cell mass in type 2 diabetes : promise and limitations of new drugs based on incretins [ J]. Endocr Rev, 2005, 29:367 -379.
  • 6Lund A, Vilsboll T, Bagger JI, et al. The separate and combined impact of the intestinal hormones, GIP, GLP- 1, and GLP- 2, on glucagons secretion in type 2 diabetes [ J ]. Am J Physiol Endocrinol Metab, 2011, 300 (6): E1038-E1046.
  • 7Baggio LL, Drucker DJ. Biology of Incretins : GLP - 1 and GI [J]. P Gastroenterology, 2007, 132: 2131- 2157.
  • 8Knop FK. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state [ J ] ? Diabetes, 2007, 56:1951-1959.
  • 9Zander M, Madsbad S, Madsen JL. Effect of 6 -week course of glucagons - like peptide 1 on glycaemic control, insulin sensitivity, and β - cell function in type 2 diabetes: a parallel - group study [ J ]. Lancet, 2002, 359:824 -830.
  • 10Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open - label, two - period, crossover noninferiority trial [ J ]. Clin Ther, 2007, 29 (11): 2333-2348.

同被引文献24

  • 1Schellenberg ES, Dryden DM, Vandermeer B, et al. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. [J]. Ann Intern Med, 2013, 159(8):543-551.
  • 2史瑞红.糖尿病护理综述[J].中外健康文摘,2013,10(9):407-409.
  • 3Tenzer-Iglesias P, Shannon MH. Managing. Hypoglycemia in primary care[J]. J Fam Pract, 2012, 61(10 Suppl):l-8.
  • 4Boussageon R, Supper I, Erpeldinger S, et al. Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review[J]. BMC Med Res Methodol, 2013, DOI:10,1 186/1 471-2 288-13-107.
  • 5Hausenioy DJ, Whittington HI, Wynne AM, et al. Dipeptidyl pepti- dase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glu- cose-dependent manner[ J ]. Cardiovasc Diabetol, 2013,12 ( 1 ) : 154- 159.
  • 6Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI[J]. Eur Heart J,2013,3d (23) : 1714- 1722.
  • 7Zhao TC. Glueagon-like peptide-1 ( GLP-1 ) and protective effects in cardiovascular disease : a new therapeutic approach for myocardial pro- tection[ J]. Cardiovasc Diabeto1,2013,12:90-93.
  • 8Cariou B. Harnessing the incretin system beyond glucose control:po- tential cardiovascular benefits of GLP-1 receptor agonists in type 2 dia- betes[J]. Diabetes Metab,2012,38(4) :298-308.
  • 9Okerson T, Chihon RJ. The cardiovascular effects of GLP-1 receptor agonists [ J]. Cardiovasc Ther,2012,30 ( 3 ) : e146-e155.
  • 10Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thronlbolysis in myocardial infarction (SAVOR- TIMI) 53 study[J]. Am Heart J,2011,162(5) :818-825. e6.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部